Cargando…

Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?

BACKGROUND: Chemoradiation is the standard treatment for anal cancer. 3D conformal radiotherapy (3D-CRT) is usually split in 2 sequences with a therapeutic break (gap) in between. Intensity-modulated radiation therapy (IMRT) makes it possible to reduce treatment time by abandoning this gap. The purp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dewas, Claire Vautravers, Maingon, Philippe, Dalban, Cécile, Petitfils, Aurélie, Peignaux, Karine, Truc, Gilles, Martin, Etienne, Khoury, Cédric, Dewas, Sylvain, Créhange, Gilles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576273/ https://www.ncbi.nlm.nih.gov/pubmed/23190693 http://dx.doi.org/10.1186/1748-717X-7-201

Ejemplares similares

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
por: Adenis, Antoine, et al.
Publicado: (2013)

Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups
por: Azelie, Caroline, et al.
Publicado: (2012)

Delineation in thoracic oncology: a prospective study of the effect of training on contour variability and dosimetric consequences
por: Dewas, Sylvain, et al.
Publicado: (2011)

Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prognostic Factors of Local Control, Overall Survival, and Toxicity
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2013)

Chemoradiation in elderly esophageal cancer patients: rationale and design of a phase I/II multicenter study (OSAGE)
por: Servagi-Vernat, Stéphanie, et al.
Publicado: (2017)

Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy
por: Dewas, Sylvain, et al.
Publicado: (2012)

Long-Term Outcomes of Chemoradiation for Anal Cancer Patients
por: Kim, Hun Jin, et al.
Publicado: (2013)

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer
por: Mirjolet, Céline, et al.
Publicado: (2016)

Impact of waiting time on nodal staging in head and neck squamous-cell carcinoma treated with radical intensity modulated radiotherapy
por: Chevalier, Cédric, et al.
Publicado: (2016)

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives
por: Schernberg, A., et al.
Publicado: (2018)

Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation
por: Meunier, Sébastien, et al.
Publicado: (2023)

Efficacy and toxicity of chemoradiation in patients with anal cancer - a retrospective analysis
por: Koerber, Stefan Alexander, et al.
Publicado: (2014)

Brachytherapy boost after chemoradiation in anal cancer: a systematic review
por: Frakulli, Rezarta, et al.
Publicado: (2018)

Penile Mondor's disease in a patient treated with radical chemoradiation for anal cancer
por: Pittaka, Maria, et al.
Publicado: (2017)

Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer
por: Robinson, Maxwell, et al.
Publicado: (2020)

Carmustine Wafer Implantation at the Era of Standardized Chemoradiation Protocol
por: Roux, Alexandre, et al.
Publicado: (2019)

Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer
por: Dapper, Hendrik, et al.
Publicado: (2018)

Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
por: Thind, Govin, et al.
Publicado: (2014)

A multi-disciplinary model of survivorship care following definitive chemoradiation for anal cancer
por: Savoie, Marissa B., et al.
Publicado: (2019)

Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis
por: Corrigan, Kelsey L., et al.
Publicado: (2022)

Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma
por: Provencher, Sawyna, et al.
Publicado: (2010)

Concurrent Chemoradiation for Vaginal Cancer
por: Miyamoto, David T., et al.
Publicado: (2013)

Cost‐effectiveness of chemoradiation followed by esophagectomy versus chemoradiation alone in squamous cell carcinoma of the esophagus
por: Salcedo, Jonathan, et al.
Publicado: (2019)

Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy
por: Silva, Ninoska N., et al.
Publicado: (2012)

Quantification of tumour heterogeneity and glucose metabolism on pre-chemoradiation PET/CT predicts survival in anal cancer
por: Afaq, A, et al.
Publicado: (2015)

Survival prediction models for patients with anal carcinoma receiving definitive chemoradiation: A population-based study
por: Wu, Yinhang, et al.
Publicado: (2020)

Racial disparities in receipt of standard chemoradiation in anal squamous cell carcinoma, an analysis of the National Cancer Database
por: Bian, Shelly X., et al.
Publicado: (2020)

Risk-adjusted chemoradiation according to human papilloma viral status for anal cancer: a pilot study
por: Chu, William, et al.
Publicado: (2023)

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)
por: Northover, J, et al.
Publicado: (2010)

Standard chemoradiation versus intensity-modulated chemoradiation: a quality of life assessment in oropharyngeal cancer patients
por: Mowry, Sarah E., et al.
Publicado: (2009)

Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer
por: Kim, Jin K, et al.
Publicado: (2022)

18F-FDG PET Predicts Hematologic Toxicity in Patients with Locally Advanced Anal Cancer Treated With Chemoradiation
por: David, John M., et al.
Publicado: (2019)

Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma
por: Grave, Athénaïs, et al.
Publicado: (2022)

Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer
por: Hernandez, Sharia, et al.
Publicado: (2023)

Chemoradiation. An Integrated Approach to Cancer Treatment
por: Duchesne, G.M.
Publicado: (1994)

Lymphopenia during chemoradiation—foe or friend
por: Patil, Vijay M, et al.
Publicado: (2020)

Dosimetric Coverage of the External Anal Sphincter by 3-Dimensional Conformal Fields in Rectal Cancer Patients Receiving Neoadjuvant Chemoradiation: Implications for the Concept of Sphincter-Preserving Radiation Therapy
por: Chen, Yi-Jen, et al.
Publicado: (2014)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]
por: Casadei-Gardini, A, et al.
Publicado: (2019)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma
por: Crosby, T D L, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_p8f7hcita478o89k71o952aqhe